Document Detail

Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study.
MedLine Citation:
PMID:  1973844     Owner:  NLM     Status:  MEDLINE    
A multi-institutional study comparing the antimanic effect of carbamazepine (CBZ) and lithium carbonate (Li) was performed using a double-blind group comparison design in a series of 105 patients with bipolar disorders. CBZ and Li were given for four weeks using a fixed-flexible method at an equipotent dose ratio of 1:1, starting from an initial dosage of 400 mg with a maximum dosage of 1200 mg. The final global improvement rate, based on the number of cases showing moderate to marked amelioration of manic symptoms, was 62% in the CBZ group and 59% in the Li group, with no significant difference being found between the two groups. Incidence of cutaneous side-effects was significantly higher in the CBZ group. The mean daily dosage and serum level of CBZ in the fourth week were 674 +/- 239 mg and 7.3 +/- 2.4 micrograms/ml respectively; these were within the therapeutic range. The daily dose and serum level of Li, however, were 710 +/- 239 mg and 0.46 +/- 0.22 mEq/l, and the Li level seemed to be too low to compare its therapeutic effect with that of CBZ. Prior to the present study, approximately 80% of the patients in both groups had been receiving antipsychotic medication, equivalent to 8.0 mg of haloperidol on average, without favorable response. This medication was maintained unchanged during treatment. While the shortcomings of the present study limit the interpretation of the data, it may be suggested that the usefulness of CBZ as a drug for the treatment of manic states is comparable to that of Li.
T Okuma; I Yamashita; R Takahashi; H Itoh; S Otsuki; S Watanabe; K Sarai; H Hazama; K Inanaga
Related Documents :
7277194 - Effects of monoamines injected into the hippocampus on hippocampal seizure discharges i...
1267534 - Studies on the neuropharmacology of tert-butylurea in mice.
8956914 - Suppression of cortical epileptic afterdischarges in developing rats by anticonvulsants...
19223154 - Involvement of nitrergic system in the anticonvulsant effect of the cannabinoid cb(1) a...
20668034 - Clinical review: thyroid hormone therapy for postoperative nonthyroidal illnesses: a sy...
14682454 - Occurrence of dermatomycoses and in-vitro therapeutic efficacy of three antifungal drug...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Pharmacopsychiatry     Volume:  23     ISSN:  0176-3679     ISO Abbreviation:  Pharmacopsychiatry     Publication Date:  1990 May 
Date Detail:
Created Date:  1990-08-29     Completed Date:  1990-08-29     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8402938     Medline TA:  Pharmacopsychiatry     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  143-50     Citation Subset:  IM    
National Center Hospital for Mental, Nervous and Muscular Disorders, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antipsychotic Agents / therapeutic use
Bipolar Disorder / drug therapy*,  psychology
Carbamazepine / adverse effects,  blood,  therapeutic use*
Double-Blind Method
Drug Therapy, Combination
Lithium / adverse effects,  blood,  therapeutic use*
Middle Aged
Psychiatric Status Rating Scales
Randomized Controlled Trials as Topic
Reg. No./Substance:
0/Antipsychotic Agents; 298-46-4/Carbamazepine; 7439-93-2/Lithium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind stu...
Next Document:  Species differences in carcinogenicity: the role of metabolism in human risk evaluation.